Mi SciELO
Servicios Personalizados
Articulo
Indicadores
Citado por SciELO
Links relacionados
Similares en SciELO
Compartir
Revista Médica Electrónica
versión On-line ISSN 1684-1824
Resumen
FERNANDEZ-MARTORI, Meilyn et al. Skin epidermoid carcinoma treated with HeberFERON®. Rev.Med.Electrón. [online]. 2022, vol.44, n.2, pp. 357-374. Epub 30-Abr-2022. ISSN 1684-1824.
Introduction:
there are few reports in the literature on the use of interferon in the treatment of the squamous cell carcinoma. In a primary care unit in Colon, Matanzas, HeberFERON® was implemented in this type of tumor with favorable experiences.
Objective:
to describe the effectiveness of HeberFERON® in epidermoid carcinoma.
Materials and methods: an observational, descriptive study was conducted in 33 epidermoid carcinoma lesions in 29 patients. The doses were 7.0 and 10.5 MUI of antiviral activity, perilesionally infiltrated three times a week for three weeks. Clinical follow-up of patients was performed before the treatment and at 16 weeks from the beginning of the treatment. The variables were: age, sex, skin phototype, origin; location, clinical type, stage and clinical response to treatment. Four categories of response were considered: complete, partial, stable and progressive disease. The objective response (complete plus partial) was included. Data were collected in a clinical record. The Microsoft Excel and SPSS programs were used for statistical processing.
Results:
65.5 % of patients were male. 58.6 % are phototype II and of urban origin. Ages ranging from 61 to 80 years (55.2 %) predominated. There was objective response in 57.6 % (five complete and 14 partials). The superficial keratotic squamous cell carcinoma and the nodular ulcerative one showed the best responses.
Conclusions:
interferon mixing was effective in all clinical subtypes of epidermoid carcinoma, although the authors suggest a second cycle of HeberFERON® or to associate it with chemotherapy when the response is not complete.
Palabras clave : epidermoid carcinoma; interferon alfa-2b; interferon gamma.